Abstract:Carvedilol is a vasodilating beta-blocker currently marketed for the treatment of mild to moderate hypertension and application is being filed to the FDA for treatment of congestive heart failure. Carvedilol reduces peripheral vascular resistance by blocking arterial alpha 1-adrenoceptors, thereby producing vasodilation, while preventing reflex tachycardia by blocking cardiac beta 1- and beta 2-adrenoceptors. In addition to the safety and efficacy of carvedilol as an antihypertensive agent, experimental studies indicate that carvedilol also provides significant cardioprotection in animal models of acute myocardial infarction as well as protection against the vascular remodelling that occurs following injury of the vasculature. Recent pharmacological studies have uncovered several novel properties of carvedilol which may function to protect the heart and vasculature from chronic pathological processes, such as ischaemia, atherosclerosis and the remodelling that occurs in the heart and blood vessels as a consequence of pressure overload, injury or shear stress. Specifically, carvedilol, likely as a result of the carbazol moiety, is a potent anti-oxidant. In physicochemical, biochemical and cellular assays carvedilol and several of its metabolites inhibit lipid peroxidation, scavenge oxygen free radicals, inhibit the formation of reactive oxygen radicals and prevent the depletion of endogenous antioxidants, such as vitamin E and glutathione. Moreover, carvedilol blocks the oxidation of low-density lipoproteins (LDL), and thereby prevents the formation of oxidized-LDL which is believed to stimulate foam cell formation and augment the development of atherosclerotic plaque. The ability of carvedilol to prevent the formation of oxidized LDL, in addition to the general anti-oxidant properties of the compound, results in the protection of the endothelium from oxygen free radical injury, and thereby prevents the subsequent events triggered by endothelial damage. Recently, carvedilol has also been shown to inhibit vascular smooth muscle cell proliferation and migration. Because carvedilol can inhibit vascular smooth muscle cell proliferation induced by a wide variety of mitogens (e.g. growth factors, angiotensin II, endothelin, thrombin), it is likely that the site of inhibition occurs at some point beyond the specific mitogen receptors, possibly at a distal common pathway that affects the smooth muscle cell cycle. These unique activities of carvedilol have also been confirmed in vivo in a rat model of neointimal formation following vascular injury by balloon angioplasty, where vascular smooth muscle cell migration and proliferation are the key processes involved in the formation of neointima leading to vascular stenosis. In this model, carvedilol suppressed neointimal growth to a remarkable extent ( > 85% inhibition of neointimal formation) at a dose that is similar to the antihypertensive dose used clinically in hypertensive patients. Taken together, these unique multiple actions of carvedilol provide not only for adequate control of elevated blood pressure, but may also provide for protection of the heart and vasculature from secondary damage due to hypertension itself, as well as from other causes, such as ischaemia, pressure overload, shear stress, vascular injury and atherosclerosis.

Effects of carvedilol on human prostate tissue contractility and stromal cell growth pointing to potential clinical implications

Carvedilol and Its New Analogs Suppress Arrhythmogenic Store Overload–induced Ca2+ Release

Effect of carvedilol on expression of Smad proteins mediated by AngⅡ in cardiac fibroblasts

Effects of Carvedilol on Circulating Levels of Endothelin and Von Willebrand Factor in Patients with Unstable Angina Pectoris

Role of Losartan and Carvedilol on in Extracellular Signal-Regulated Kinases in Myocardium of Spontaneously Hypertensive Rats

Carvedilol inhibits EGF-mediated JB6 P+ colony formation through a mechanism independent of adrenoceptors

Carvedilol induces biased β1 adrenergic receptor-nitric oxide synthase 3-cyclic guanylyl monophosphate signalling to promote cardiac contractility

Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection

Protective effects of S-carvedilol on doxorubicin-induced damages to human umbilical vein endothelial cells and rats.

Comparison Of Low And High Doses Of Carvedilol On Restoration Of Cardiac Function And Calcium-Handling Proteins In Rat Failing Heart

Effects of Carvedilol on the Renal Function in Patients with Essential Hypertension

The Effects of Carvedilol on Intracellular Free Calcium Concentration in Human Atrial Myocyte by Confocal Microscopy

The β-Blocker Carvedilol Prevents Benzo(a)pyrene-Induced Lung Toxicity, Inflammation and Carcinogenesis

Effects of Carvedilol on M2 Receptors and Cholinesterase-Positive Nerves in Adriamycin-Induced Rat Failing Heart

Effects of Carvedilol on Cardiac Cytokines Expression and Remodeling in Rat with Acute Myocardial Infarction

Changes of Calcium Handling Protein after Acute Myocardial Infarction in Rats and Effect of Carvedilol

The Effects of Combined Versus Selective Adrenergic Blockade on Left Ventricular and Systemic Hemodynamics, Myocardial Substrate Preference, and Regional Perfusion in Conscious Dogs with Dilated Cardiomyopathy

In vitro neuroendocrine differentiation of BPH-1 cells under beta2 adrenergic receptor stimulation

Effects of Α1-Adrenoceptor Antagonists on Cell Proliferation and Apoptosis in Prostate Cancer

Effect of Carvedilol and Metoprolol on Blood Pressure, Blood Flow, and Vascular Resistance

The effects of carvedilol administration on cardiopulmonary resuscitation in a rat model of cardiac arrest induced by airway obstruction